Immunocore (NASDAQ:IMCR) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR) in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a $100.00 target price on the stock.

Other equities analysts have also issued reports about the company. Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. Needham & Company LLC reissued a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Price Performance

Immunocore stock opened at $29.05 on Wednesday. Immunocore has a one year low of $27.19 and a one year high of $66.00. The business has a fifty day moving average price of $30.13 and a 200-day moving average price of $31.45. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The firm has a market capitalization of $1.45 billion, a P/E ratio of -30.58 and a beta of 0.79.

Institutional Investors Weigh In On Immunocore

Large investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its position in Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after purchasing an additional 520,950 shares in the last quarter. State Street Corp raised its position in Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company’s stock valued at $2,387,000 after purchasing an additional 29,897 shares in the last quarter. Principal Financial Group Inc. raised its position in Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in Immunocore by 125.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock valued at $1,463,000 after purchasing an additional 27,598 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Immunocore by 7,437.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock worth $2,872,000 after buying an additional 91,033 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.